Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―― 20 mg ...

Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically ...

Fulcrum Therapeutics (NASDAQ:FULC) shared full 12-week results from the 20-mg cohort of its phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease, expanding on partial data ...

Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease ...

Fulcrum, the AI-powered field process management and data collection platform, today announced it has acquired Wildnote, an environmental software company focused on regulatory compliance with field ...

Fulcrum Therapeutics FULC, a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter’s loss is pinned at ...

Fulcrum Therapeutics’ sickle cell disease therapy has been placed on a clinical hold by the FDA, capping off a tough week for drug development for the condition that saw three separate treatments ...

Fulcrum Therapeutics announced a pair of executive appointments Monday morning. The clinical-stage biopharma company named Isabel Kalofonos as chief commercial officer and Heather Faulds as chief ...

The partnership with Northmarq will enable Fulcrum Lending to underwrite loans through the platform directly, completing Fulcrum Lending’s offering as a full-service digital lender. Fulcrum Lending ...

Fulcrum has released three new models of its previously-budget Racing Quattro wheelset. In addition to updating the existing 35mm-depth alloy version, the Quattro range receives two carbon 40mm-deep ...

Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare ...